Norgine strengthens rare disease portfolio with acquisition of Theravia

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

NORGINE-Acq-Theravia

More Like This

PR Newswire associated0

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor - licenced to Norgine for commercialisation in Europe.

PR Newswire associated0

Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand

PR Newswire associated0

Norgine Announces Appointment of New CEO Janneke van der Kamp

Ferring Pharmaceuticals bolsters global gene therapy supply chain with European manufacturing facility

Business Wire associated0

Avanzanite Bioscience Expands Partnership With Advicenne in Additional European Countries

Kyowa Kirin International and NewBridge Pharmaceuticals Enter Into Agreement to Improve Access to Medicines for Rare Disease Patients Across Middle East and North Africa

Kyowa Kirin Successfully Completes Acquisition of Orchard Therapeutics, a Global Gene Therapy Leader for Rare Diseases

PR Newswire associated0

Norgine B.V. submits Marketing Authorisation Application via Project Orbis for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma